Document is current
Any future updates will be listed below
-
Authors
Van Den Eeckhout, Bram https://orcid.org/0000-0002-6729-8951
Van Hoecke, Lien https://orcid.org/0000-0001-8602-4211
Burg, Elianne
Van Lint, Sandra https://orcid.org/0000-0001-9767-5386
Peelman, Frank
Kley, Niko
Uzé, Gilles
Saelens, Xavier https://orcid.org/0000-0002-3861-6965
Tavernier, Jan https://orcid.org/0000-0002-7609-6462
Gerlo, Sarah https://orcid.org/0000-0002-1628-6088
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek
Universiteit Gent
European Research Council Orionis Biosciences Inc.
- License Information
-
More Information
Article History
Received: 17 September 2019
Accepted: 19 June 2020
First Online: 23 July 2020
Competing interests
: Financial interests: N.K. and J.T. are affiliated with Orionis Biosciences Inc. as scientific advisor and/or employee and hold equity interests in Orionis Biosciences Inc. N.K., J.T., S.G., F.P., and G.U. are inventors on the following patent applications related to the work presented in this paper: WO/2015/007542: Targeted modified IL-1 family members. Applicants: VIB VZW, Universiteit Gent, Centre National de la Recherche Scientifique, Université Montpellier, Centre Hospitalier Regional Universitaire de Montpellier. Inventors: J.T., S.G., F.P., and G.U. This patent application describes IL-1β mutants with reduced bioactivity that can be activated by targeting as demonstrated in this paper for IL-1β Q148G. WO/2017/134306: CD8 binding agents. Applicants: Orionis Biosciences Inc., VIB VZW, Universiteit Gent. Inventors: J.T., Anje Cauwels, N.K., and S.G. This patent application describes sdAbs that bind CD8 and that can be used to target mutant IL-1β to CTLs as demonstrated in this paper. The authors have no other, nonfinancial, competing interests to declare.
